241 related articles for article (PubMed ID: 8362600)
61. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.
Jacobs EL; Clare-Salzler MJ; Chopra IJ; Figlin RA
J Immunother (1991); 1991 Dec; 10(6):448-55. PubMed ID: 1768679
[TBL] [Abstract][Full Text] [Related]
62. Treatment of metastatic colorectal cancer patients with 5-fluorouracil in combination with recombinant subcutaneous human interleukin-2 and alpha-interferon.
Atzpodien J; Kirchner H; Hänninen EL; Menzel T; Deckert M; Franzke A; Schomburg A; Poliwoda H
Oncology; 1994; 51(3):273-5. PubMed ID: 8196911
[TBL] [Abstract][Full Text] [Related]
63. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
64. Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma.
Antoine EC; Benhammouda A; Bernard A; Youssef A; Mortier N; Gozy M; Nizri D; Auclerc G; Rocher MA; Soubrane CL; Weil M; Khayat D
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S16-21. PubMed ID: 9457388
[TBL] [Abstract][Full Text] [Related]
65. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
66. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M
Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781
[TBL] [Abstract][Full Text] [Related]
67. Phase I study of sequentially administered recombinant tumor necrosis factor and recombinant interleukin-2.
Krigel RL; Padavic-Shaller K; Toomey C; Comis RL; Weiner LM
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):161-70. PubMed ID: 7613642
[TBL] [Abstract][Full Text] [Related]
68. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
[TBL] [Abstract][Full Text] [Related]
69. In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2.
Meffert M; Hanninen EL; Menzel T; Schomburg A; Duensing S; Dallmann I; Grosse J; Vocke S; Buer J; Deckert M
Cancer Biother; 1994; 9(4):307-16. PubMed ID: 7719378
[TBL] [Abstract][Full Text] [Related]
70. Dose distribution of low-dose subcutaneous recombinant interleukin-2 affects the secondary release of interferon-gamma in vivo.
Meffert M; Duensing S; Atzpodien J
Cancer Biother Radiopharm; 1997 Jun; 12(3):149-55. PubMed ID: 10851461
[TBL] [Abstract][Full Text] [Related]
71. Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
Keilholz U; Stoter G; Punt CJ; Scheibenbogen C; Lejeune F; Eggermont AM
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S22-8. PubMed ID: 9457389
[TBL] [Abstract][Full Text] [Related]
72. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.
Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J
Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401
[TBL] [Abstract][Full Text] [Related]
73. Phase I study of i.v. administered recombinant gamma interferon in cancer patients.
Kurzrock R; Quesada JR; Rosenblum MG; Sherwin SA; Gutterman JU
Cancer Treat Rep; 1986 Dec; 70(12):1357-64. PubMed ID: 3098417
[TBL] [Abstract][Full Text] [Related]
74. The out-patient use of recombinant human interleukin-2 and interferon alfa-2b in advanced malignancies.
Atzpodien J; Kirchner H
Eur J Cancer; 1991; 27 Suppl 4():S88-91; discussion S92. PubMed ID: 1799491
[TBL] [Abstract][Full Text] [Related]
75. Recombinant interferon alpha and gamma in combination as treatment for metastatic renal cell carcinoma.
Quesada JR; Evans L; Saks SR; Gutterman JU
J Biol Response Mod; 1988 Jun; 7(3):234-9. PubMed ID: 3134511
[TBL] [Abstract][Full Text] [Related]
76. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
77. Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum.
Elias D; Farace F; Triebel F; Hattchouel JM; Pignon JP; Lecesne A; Rougier P; Lasser P; Duvillard P; Escudier B
J Am Coll Surg; 1995 Oct; 181(4):303-10. PubMed ID: 7551323
[TBL] [Abstract][Full Text] [Related]
78. Recombinant interleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation. A case report of cardiovascular toxicity with serial echocardiographic evaluation.
Schechter D; Nagler A; Ackerstein A; Nassar H; Admon D; Naparstek E; Rein AJ
Cardiology; 1992; 80(3-4):168-71. PubMed ID: 1511464
[TBL] [Abstract][Full Text] [Related]
79. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
[TBL] [Abstract][Full Text] [Related]
80. Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group.
Rogers E; Bredin H; Butler M; Corcoran M; Egan E; Fennelly J; Grainger R; Aleer SM; Dermott TM; Mullins G; Tanner A; Twomey A; Thornhill J
Eur Urol; 2000 Mar; 37(3):261-6. PubMed ID: 10720849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
